Evidence map›Paper›PMID 18221507›Full record

ArticleBMC genomics2008

Development of a human mitochondrial oligonucleotide microarray (h-MitoArray) and gene expression analysis of fibroblast cell lines from 13 patients with isolated F1Fo ATP synthase deficiency.

Alena Cízková, Viktor Stránecký, Robert Ivánek, Hana Hartmannová, Lenka Nosková, Lenka Piherová, Markéta Tesarová, Hana Hansíková, Tomás Honzík, Jirí Zeman and 8 more

Open access · goldAbstract readValidation Study
In one paragraph

Article in BMC genomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. DNA microarray-based gene expression profiling of estrogenic chemicals.Cellular and molecular life sciences : CMLS · 2014
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 4 countries.

Alena CízkováCenter for Applied Genomics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. acizk@LF1.cuni.cz
Viktor Stránecký
Robert Ivánek
Hana Hartmannová
Lenka Nosková
Lenka Piherová
Markéta Tesarová
Hana Hansíková
Tomás Honzík
Jirí Zeman
Petr Divina
Andrea Potocká
Jan Paul
Wolfgang Sperl
Johannes A Mayr
Sara Seneca
Josef Houstĕk
Stanislav Kmoch
Charles University · CZParacelsus Medical University · ATBioEnergetics (United States) · USCzech Academy of Sciences · CZCzech Academy of Sciences, Institute of Physiology · CZInstitute of Molecular Genetics · RU

Funding

Family care of brain tumor patientsF31NR008069 · NINR · MICHIGAN STATE UNIVERSITY · PI SHERWOOD, PAULA R · 2002 to 2003
$49k
NINR NIH HHS F31 NR008069
6 · The paper itself

Abstract

backgroundTo strengthen research and differential diagnostics of mitochondrial disorders, we constructed and validated an oligonucleotide microarray (h-MitoArray) allowing expression analysis of 1632 human genes involved in mitochondrial biology, cell cycle regulation, signal transduction and apoptosis. Using h-MitoArray we analyzed gene expression profiles in 9 control and 13 fibroblast cell lines from patients with F1Fo ATP synthase deficiency consisting of 2 patients with mt9205deltaTA microdeletion and a genetically heterogeneous group of 11 patients with not yet characterized nuclear defects. Analysing gene expression profiles, we attempted to classify patients into expected defect specific subgroups, and subsequently reveal group specific compensatory changes, identify potential phenotype causing pathways and define candidate disease causing genes.

resultsMolecular studies, in combination with unsupervised clustering methods, defined three subgroups of patient cell lines--M group with mtDNA mutation and N1 and N2 groups with nuclear defect. Comparison of expression profiles and functional annotation, gene enrichment and pathway analyses of differentially expressed genes revealed in the M group a transcription profile suggestive of synchronized suppression of mitochondrial biogenesis and G1/S arrest. The N1 group showed elevated expression of complex I and reduced expression of complexes III, V, and V-type ATP synthase subunit genes, reduced expression of genes involved in phosphorylation dependent signaling along MAPK, Jak-STAT, JNK, and p38 MAP kinase pathways, signs of activated apoptosis and oxidative stress resembling phenotype of premature senescent fibroblasts. No specific functionally meaningful changes, except of signs of activated apoptosis, were detected in the N2 group. Evaluation of individual gene expression profiles confirmed already known ATP6/ATP8 defect in patients from the M group and indicated several candidate disease causing genes for nuclear defects.

conclusionOur analysis showed that deficiency in the ATP synthase protein complex amount is generally accompanied by only minor changes in expression of ATP synthase related genes. It also suggested that the site (mtDNA vs nuclear DNA) and the severity (ATP synthase content) of the underlying defect have diverse effects on cellular gene expression phenotypes, which warrants further investigation of cell cycle regulatory and signal transduction pathways in other OXPHOS disorders and related pharmacological models.

Indexed as

Cell LineCluster AnalysisDNA, MitochondrialFibroblastsGene Expression ProfilingGenome, MitochondrialHumansMitochondrial DiseasesMitochondrial Proton-Translocating ATPasesModels, GeneticOligonucleotide Array Sequence AnalysisPhenotypePrincipal Component AnalysisSequence DeletionDNA, MitochondrialF1F0-ATP synthaseMitochondrial Proton-Translocating ATPases

Identifiers

PMID18221507
PMCPMC2267714
OpenAlexW2013770299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.